Uni-Bio Science Group Limited (0690.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$0.066 (-2.94%) as of
Key statistics
- Market cap
- 394.10M
- P/E (TTM)
- 6.60
- EPS (TTM)
- 0.010
- Dividend yield
- 4.60%
- 52-week range
- 0.049 – 0.134
- Beta
- -0.15
- Revenue (TTM)
- 549.77M
- Profit margin
- 8.83%
- Volume
- 2.94M
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in Hong Kong, and People's Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, for treating osteoporosis and bone pain. It also offers medical aesthetics. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sha Tin, Hong Kong
- Employees
- 568
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.